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Objectives: To synthesize dihydro-pyrimidine-5-
carbonitrile derivatives (5e23), as an extension of the
previous series, and to evaluate their anticonvulsant
potential.
Methods: The designed compounds were synthesized and
characterized using infrared (IR), nuclear magnetic
resonance (NMR) and mass spectroscopy and were
evaluated for anticonvulsant activity using the maximal
electroshock seizure (MES) and subcutaneous pentylene-
tetrazole (scPTZ) methods. Compounds with appreciable
activity were investigated for their neurotoxicity using the
rotarod test.
Results: Compounds 17 and 23 were found to be most
active at a dose of 30 mg kg1 at 0.5 h and 4 h in both
models and did not exhibit motor impairment activity,
even at higher doses.
Conclusion: The newer designed compounds were found
to be better than previously reported compounds. This
study also shows that increased lipophilicity is directly
related to the anticonvulsant activity.
Keywords:Anticonvulsant; Epilepsy; Infrared; Neurotoxicity;
Nuclear magnetic resonance
 2015 The Authors.
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Figure 2: Anticonvulsant drugs bearing dihydropyrimidine ring.Hybrid molecules, an emerging trend containing two or
more structural domains, acting on the same or different
targets have been reported to exhibit diverse pharmacolog-
ical activities, including anticonvulsant activity. Recently,
following the hybrid approach, compounds containing a
combination of pyridines and pyrrolidones1 (I) and thiazoles
coupled to an oxoquinazoline moiety (II) have been
synthesized, some of which exhibit comparable or even
higher anticonvulsant activity2 than the standard drug
phenytoin (Figure 1).
Among various heterocycles, pyrimidine derivatives are
quite significant because they have been found to possess
diverse pharmacological activities.3e5 The well-known anti-
convulsant drugs phenobarbitone (III) and primidone (IV)
possess a dihydropyrimidine ring (Figure 2).
Similarly, Schiff bases have been reported to elicit such
activities.6,7
Due to the anticonvulsant activities of pyrimidine and
Schiff bases, synergistic activity was expected upon attaching
the twomoieties. In this context, we previously synthesized 6-
oxo-4-(4-methoxy-phenyl)-1,6-dihydropyrimidine-5-
carbonitrile derivatives as anticonvulsants. Among these
derivatives, compounds with bromo (V) and nitro substitu-
tion (VI) on ring C were found to be the most active
(Figure 3) with lower neurotoxicity.8
Following this,8 we have now synthesized newer
derivatives (5e23) by replacing the methoxy group with
hydrogen and chloro groups on ring A (Figure 4) to
examine the effect of increasing the lipophilicity on
anticonvulsant activity using the MES9,10 and scPTZ11
methods. Compounds with appreciable activity were
investigated for neurotoxicity using the rotarod12 test.
Materials and Methods
Chemistry
The reagents/chemicals/solvents used during the course of
these studies were procured from Merck (India), SD Fine
and CDH Laboratories as ‘synthesis grade’ and were used
without purification. Melting points (mp) were recorded in
open glass capillaries using a Kjeldahl flask containing liquidN
N
CN
O
O
OH
I
Figure 1: Hybrid molecules reporparaffin. The purity of the compounds was investigated by
thin layer chromatography (TLC) on silica gel G plates using
benzene:acetone (7:3) as the solvent system. Spots were
located either under ultraviolet (UV) light or through
exposure to iodine vapours.
IR spectra were recorded using a Bruker alpha-T spec-
trophotometer. 1H-NMR spectra were recorded on a Bruker
Avance 400 MHz instrument in CDCl3 or DMSO-d6 using
tetramethylsilane [(CH3)4Si] (TMS) as an internal standard.
The 13C-NMR spectra of the compounds were recorded on a
Bruker Avance 100 MHz instrument in DMSO-d6. Chemical
shifts (d) are reported in parts per million (ppm) downfield
from TMS, and coupling constants (J) are reported in hertz.
Mass spectra were recorded using a Waters SYNAPT
UPLC-MS/MS operating with Mass Linux V4.1 software.
Elemental analysis (C, H, N) was performed using a Perki-
nElmer model 240 analyser, and elements were found within
 0.4% of the theoretical values.General procedure for the synthesis of 2-mercapto-6-oxo-4-aryl-1,6-
dihydropyrimidine-5-carbonitrile derivatives (1e2)
These derivatives were synthesized following the previ-
ously reported method.132-Mercapto-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitrile
(1):. mp: 299e300C134-(4-Chlorophenyl)-2-mercapto-6-oxo-1,6-dihydropyrimidine-5-
carbonitrile (2). mp: 281e282C13N
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Figure 3: Previously reported anticonvulsants (Schiff’s base dihydropyrimidine hybrids).
Synthesis and anticonvulsant activity 439General procedure for the synthesis of 2-hydrazinyl-6-oxo-4-aryl
-1,6-dihydropyrimidine-5-carbonitrile (3e4)
These compounds were synthesized following the previ-
ously reported method.13
2-Hydrazinyl-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitrile
(3):. mp: 219e220C13
4-(4-Chlorophenyl)-2-hydrazinyl-6-oxo-1,6-dihydropyrimidine-5-
carbonitrile (4):. mp: 301e302C13
General procedure for the synthesis of 6-oxo-4-aryl-1,6-
dihydropyrimidine-5-carbonitrile derivatives (5e23)
Compound 3 or 4 (1 mmol) was dissolved in a mixture of
acetic acid and absolute ethanol (2:8). Substituted aceto-
phenone was added to this solution and refluxed for 2e3 h.
The solvent was concentrated and kept in a refrigerator
overnight. The precipitate was separated, filtered and
recrystallized from methanol (Scheme 1).
6-Oxo-4-phenyl-2-(2-(1-phenylethylidene)hydrazinyl)-1,6-
dihydropyrimidine-5-carbonitrile (5). mp: 190e192 C; Rf: 0.55;
Yield: 42%; IR(cm1): 3285 (CONH), 3259 (NH), 2215
(C^N), 1670 (C]O), 1628 (C]N); 1H NMR (d, ppm)
(400 MHz, DMSO-d6): 2.36 (s, 3H, CH3), 7.39 (m, 3H,
H30,40,50 Arylidene ring), 7.49 (m, 3H, H3,4,5 Phenyl ring), 7.83
(d, 2H, J¼ 6.4 Hz, H2,6 Phenyl ring), 8.08 (d, 2H, J¼ 7.6 Hz,
H20,60 Arylidene ring), 11.81 (bs, 1H, NH), 12.07 (bs, 1H,
CONH); MS: m/z 330 (Mþþ1). Anal. Calcd. for
C19H15N5O: C, 69.29; H, 4.59; N, 21.26. Found: C, 69.27; H,
4.55; N, 4.56.
6-Oxo-4-phenyl-2-(2-(1-p-tolylethylidene)hydrazinyl)-1,6-
dihydropyrimidine-5-carbonitrile (6). mp: 220e222 C; Rf: 0.48;
Yield: 46%; IR(cm1): 3280 (CONH), 3264 (NH), 2212
(C^N), 1665 (C]O), 1622 (C]N); 1H NMR (d, ppm)
(400 MHz, DMSO-d6): 2.32 (s, 3H, CH3), 2.34 (s, 3H, CH3),
7.19 (d, 2H, J ¼ 8.0 Hz, H30,50 Arylidene ring), 7.49 (m, 3H,
H3,4,5 Phenyl ring), 7.83 (d, 2H, J¼ 6.8 Hz, H2,6 Phenyl ring),
7.99 (d, 2H, J ¼ 8.0 Hz, H20,60 Arylidene ring), 11.47 (bs, 1H,
NH), 12.05 (bs,1H, CONH); MS: m/z 344 (Mþþ1). Anal.
Calcd. for C20H17N5O: C, 69.96; H, 4.99; N, 20.40. Found:
C, 69.97; H, 4.97; N, 20.38.
2-(2-(1-(4-Hydroxyphenyl)ethylidene)hydrazinyl)-6-oxo-4-phenyl-
1,6-dihydropyrimidine-5-carbonitrile (7). mp: 272e274 C; Rf:
0.40; Yield: 43%; IR(cm1): 3390 (OH), 3286 (CONH), 3270
(NH), 2214 (C^N), 1668 (C]O), 1626 (C]N); 1HNMR (d,ppm) (400 MHz, DMSO-d6): 2.30 (s, 3H, CH3), 6.74 (d, 2H,
J ¼ 8.8 Hz, H30,50 Arylidene ring), 7.49 (m, 3H, H3,4,5 Phenyl
ring), 7.82 (d, 2H, J ¼ 6.4 Hz, H2,6 Phenyl ring), 7.94 (d, 2H,
J ¼ 8.8 Hz, H20,60 Arylidene ring), 9.81 (bs, 1H, OH), 11.39
(bs, 1H, NH), 11.92 (bs, 1H, CONH); MS: m/z 346 (Mþþ1).
Anal. Calcd. for C19H15N5O2: C, 66.08; H, 4.38; N, 20.28.
Found: C, 66.05; H, 4.40; N, 20.29.
2-(2-(1-(4-Methoxyphenyl)ethylidene)hydrazinyl)-6-oxo-4-phenyl-
1,6-dihydropyrimidine-5-carbonitrile (8). mp: 192e194; Rf:
0.53; Yield: 44%; IR(cm1): 3292 (CONH), 3268 (NH), 2219
(C^N), 1665 (C]O), 1632 (C]N); 1H NMR (d, ppm)
(400 MHz, DMSO-d6): 2.33 (s, 3H, CH3), 3.78 (s,
3H,OCH3), 6.92 (d, 2H, J ¼ 8.8 Hz, H30,50 Arylidene ring),
7.51 (m, 3H, H3,4,5 Phenyl ring), 7.83 (d, 2H, J¼ 6.8 Hz, H2,6
Phenyl ring), 8.06 (d, 2H, J ¼ 8.4 Hz, H20,60 Arylidene ring),
11.43 (bs, 1H, NH), 12.03 (bs, 1H, CONH); MS: m/z 360
(Mþþ1). Anal. Calcd. for C20H17N5O2: C, 66.84; H, 4.77; N,
19.49. Found: C, 66.87; H, 4.75; N, 19.47.
2-(2-(1-(2,4-Dimethoxyphenyl)ethylidene)hydrazinyl)-6-oxo-4-
phenyl-1,6dihydropyrimidine-5-carbonitrile (9). mp: 212e214 C;
Rf: 0.70; Yield: 48%; IR(cm
1): 3282 (CONH), 3275 (NH),
2208 (C^N), 1659 (C]O), 1628 (C]N), 1603 (Ar); 1H
NMR (d, ppm) (400 MHz, DMSO-d6): 2.26 (s, 3H, CH3),
3.76 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 6.45 (d, 1H,
J ¼ 8.0 Hz, H50 Arylidene ring), 6.50 (s, 1H, H30 Arylidene
ring), 7.45 (m, 3H, H3,4,5 Phenyl ring), 7.61 (d, 1H,
J ¼ 8.0 Hz, H60 Arylidene ring), 7.80 (d, 2H, J ¼ 6.8 Hz, H2,6
Phenyl ring), 11.35 (bs, 2H, NH & CONH); MS: m/z 390
(Mþþ1). Anal. Calcd. for C21H19N5O3: C, 64.77; H, 4.92; N,
17.98. Found: C, 64.78; H, 49.94; N, 17.96.
2-(2-(1-(4-Chlorophenyl)ethylidene)hydrazinyl)-6-oxo-4-phenyl-
1,6-dihydropyrimidine-5-carbonitrile (10). mp: 260e262 C; Rf:
0.69; Yield: 30%; IR(cm1): 3309 (CONH), 3275 (NH), 2217
(C^N), 1677 (C]O), 1624 (C]N), 1599 (Ar); 1H NMR (d,
ppm) (400 MHz, DMSO-d6): 2.35 (s, 3H, CH3), 7.44 (d, 2H,
J ¼ 8.8 Hz, H30,50 Arylidene ring), 7.49 (m, 3H, H3,4,5 Phenyl
ring), 7.83 (d, 2H, J ¼ 6.4 Hz, H2,6 Phenyl ring), 8.15 (d, 2H,
J ¼ 8.4 Hz, H20,60 Arylidene ring), 11.54 (bs, 1H, NH), 12.25
(bs, 1H, CONH); MS: m/z 364 (Mþþ1), 366 (Mþþ2). Anal.
Calcd. for C19H14ClN5O: C, 62.73; H, 3.88; N, 19.25. Found:
C, 62.75; H, 3.89; N, 19.28.
2-(2-(1-(4-Fluorophenyl)ethylidene)hydrazinyl)-6-oxo-4-phenyl-1,6-
dihydropyrimidine-5-carbonitrile (11). mp: 244e246 C; Rf: 0.53;
Yield: 92%; IR(cm1): 3290 (CONH), 3261 (NH), 2224
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Figure 4: Representation of title compound.
M.R. Ali et al.440(C^N), 1699 (C]O), 1630 (C]N), 1601 (Ar); 1H NMR (d,
ppm) (400 MHz, DMSO-d6): 2.33 (s, 3H, CH3), 7.02 (t, 2H,
J ¼ 8.8 Hz, H30,50 Arylidene ring), 7.41 (m, 3H, H3,4,5 Phenyl
ring), 7.81 (d, 2H, J¼ 6.4 Hz, H2,6 Phenyl ring), 8.02 (m, 2H,
H20,60 Arylidene ring), 11.62 (bs, 2H, NH&CONH);MS:m/z
348 (Mþþ1). Anal. Calcd. for C19H14FN5O: C, 65.70; H,
4.06; N, 20.16. Found: C, 65.68; H, 4.04; N, 20.18.
2-(2-(1-(4-Aminophenyl)ethylidene)hydrazinyl)-6-oxo-4-phenyl-1,6-
dihydropyrimidine-5-carbonitrile (12). mp: 292e294 C; Rf: 0.57;
Yield: 43%; IR(cm1): 3355 & 3309 (NH2), 3281 (CONH),
3254 (NH), 2218 (C^N), 1688 (C]O), 1622 (C]N), 1606
(Ar); 1H NMR (d, ppm) (400 MHz, DMSO-d6): 2.31 (s, 3H,
CH3), 5.35 (s, 2H, NH2), 7.40 (m, 3H, H3,4,5 Phenyl ring),
7.56 (d, 2H, J ¼ 8.4 Hz, H30,50 Arylidene ring), 7.81 (d, 2H,
J ¼ 6.8 Hz, H2,6 Phenyl ring), 7.88 (d, 2H, J ¼ 8.4 Hz, H20,60
Arylidene ring), 11.34 (bs,1H, NH), 11.52 (bs, 1H, CONH);
MS:m/z 344(Mþþ1). Anal. Calcd. for C19H16N6O: C, 66.27;
H, 4.68; N, 24.40. Found: C, 66.28; H, 4.70; N, 24.39.
2-(2-(1-(4-Nitrophenyl)ethylidene)hydrazinyl)-6-oxo-4-phenyl-1,6-
dihydropyrimidine-5-carbonitrile (13). mp: 234e236 C; Rf: 0.48;
Yield: 53%; IR(cm1): 3323 (CONH), 3278 (NH), 2217
(C^N), 1673 (C]O), 1626 (C]N), 1591 (Ar); 1H NMR (d,
ppm) (400 MHz, DMSO-d6): 2.40 (s, 3H, CH3), 7.45 (m, 3H,
H3,4,5 Phenyl ring), 7.83 (d, 2H, J¼ 6.0 Hz, H2,6 Phenyl ring),
8.14 (d, 2H, J ¼ 8.4 Hz, H20,60 Arylidene ring), 8.29 (d, 2H,
J ¼ 8.0 Hz, H30,50 Arylidene ring), 11.60 (bs, 1H, NH), 12.18
(bs,1H, CONH); MS: m/z 375 (Mþþ1). Anal. Calcd. for
C19H14N6O3: C, 60.96; H, 3.77; N, 22.45. Found: C, 60.97;
H, 3.75; N, 22.46.
4-(4-Chlorophenyl)-6-oxo-2-(2-(1-phenylethylidene)hydrazinyl)-
1,6-dihydropyrimidine-5-carbonitrile (14). mp: 230e232 C; Rf:
0.70; Yield: 44%; IR (cm1): 3288 (CONH), 3209 (NH),
2213 (C^N), 1668 (C]O), 1625 (C]N), 1608 (Ar); 1H
NMR (d, ppm) (400 MHz, DMSO-d6): 2.36 (s, 3H, CH3),
7.39 (m, 3H, H30,40,50 Arylidene ring), 7.59 (d, 2H, J¼ 8.8 Hz,
H3,5 Phenyl ring), 7.86 (d,2H, J ¼ 8.4 Hz, H2,6 Phenyl ring),
8.09 (d,2H, J ¼ 8.0 Hz, H20,60 Arylidene ring), 11.55 (bs, 1H,
NH), 12.13.(bs, 1H, CONH); 13C-NMR (100 MHz, DMSO-
d6): 15.26, 87.41, 117.30, 127.69, 128.59, 128.93, 130.24,
130.71, 135.44, 136.37, 137.53, 154.62, 161.74, 169.82; MS:
m/z 364 (Mþþ1), 366 (Mþþ2). Anal. Calcd. for:
C19H14ClN5O: C, 62.73; H, 3.88; N, 19.25. Found: C, 62.71;
H, 3.89; N, 19.27.
4-(4-Chlorophenyl)-6-oxo-2-(2-(1-p-tolylethylidene)hydrazinyl)-
1,6-dihydropyrimidine-5-carbonitrile (15). mp: 240e244 C; Rf::
0.57; Yield: 90%; IR (cm1): 3290 (CONH), 3240 (NH),2213 (C^N), 1667 (C]O), 1628 (C]N); 1H NMR (d, ppm)
(400 MHz, DMSO-d6): 2.33 (s, 3H, CH3), 2.35 (s, 3H, CH3),
7.23 (d, 2H, J ¼ 8.0 Hz, H30,50 Arylidene ring), 7.59 (d, 2H,
J ¼ 8.4 Hz, H3,5 Phenyl ring), 7.85 (d, 2H, J ¼ 8.4 Hz, H2,6
Phenyl ring), 7.98 (d,2H, J ¼ 8.0 Hz, H20,60 Arylidene ring),
11.51 (bs, 1H, NH), 12.03 (bs, 1H, CONH); MS: m/z 378
(Mþþ1), 380 (Mþþ2). Anal. Calcd. for C20H16ClN5O: C,
63.58; H, 4.27; N, 18.54. Found: C, 63.55; H, 4.28; N, 18.56.
4-(4-Chlorophenyl)-2-(2-(1-(4-hydroxyphenyl)ethylidene)hydra-
zinyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (16). mp: 304e
306 C; Rf: 0.65; Yield: 76%; IR(cm1): 3430 (OH), 3280
(CONH), 3245 (NH), 2219 (C^N), 1655 (C]O), 1630 (C]
N), 1600 (Ar); 1HNMR (d, ppm) (400MHz, DMSO-d6): 2.29
(s, 3H, CH3), 6.74 (d, 2H, J ¼ 8.8 Hz, H30,50 Arylidene ring),
7.59 (d, 2H, J ¼ 8.4 Hz, H3,5, Phenyl ring), 7.85 (d, 2H,
J ¼ 8.4 Hz, H2,6 Phenyl ring), 7.94 (d, 2H, J ¼ 8.4 Hz, H20,60
Arylidene ring), 9.81 (s, 1H, OH), 11.92 (bs, 2H, NH &
CONH); MS: m/z 380 (Mþþ1), 382 (Mþþ2). Anal. Calcd.
for C19H14ClN5O2: C, 60.09; H, 3.72; N, 18.44. Found: C,
6.07; H, 3.70; N, 18.45.
4-(4-Chlorophenyl)-2-(2-(1-(4-nitrophenyl)ethylidene)hydrazinyl)-
6-oxo-1,6-dihydropyrimidine-5-carbonitrile (17). mp: 258e
260 C; Rf: 0.52; Yield: 78%; IR(cm1): 3286 (CONH), 3256
(NH), 2219 (C^N), 1670 (C]O), 1626 (C]N); 1HNMR (d,
ppm) (400 MHz, DMSO-d6): 2.41 (s, 3H, CH3), 7.60 (d, 2H,
J ¼ 8.4 Hz, H3,5 Phenyl ring), 7.87 (d, 2H, J ¼ 8.4 Hz, H2,6
Phenyl ring), 8.20 (d, 2H, J ¼ 8.8 Hz, H20,60 Arylidene ring),
8.37 (d, 2H, J ¼ 8.8 Hz, H30,50 Arylidene ring), 12.05 (bs, 2H,
NH & CONH); MS: m/z 409 (Mþþ1), 411 (Mþþ2). Anal.
Calcd. for C19H13ClN6O3: C, 55.82; H, 3.21; N, 20.56.
Found: C, 55.80; H, 3.20; N, 20.58.
4-(4-Chlorophenyl)-2-(2-(1-(4-methoxyphenyl)ethylidene)hydra-
zinyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (18). mp: 242e
244 C; Rf: 0.50; Yield: 79%; IR(cm1): 3148 (CONH), 3137
(NH), 2222 (C^N), 1703 (C]O), 1623 (C]N), 1600 (Ar);
1H NMR (d, ppm) (400 MHz, DMSO-d6): 2.32 (s, 3H, CH3),
3.77 (s, 3H, OCH3), 6.91 (d, 2H, J ¼ 8.8 Hz, H3050 Arylidene
ring), 7.59 (d, 2H, J ¼ 8.4 Hz, H3,5 Phenyl ring), 7.85 (d, 2H,
J ¼ 8.8 Hz, H2,6 Phenyl ring), 8.05 (d, 2H, J ¼ 8.8 Hz, H20,60
Arylidene ring), 11.83 (bs, 2H, NH & CONH); MS: m/z 394
(Mþþ1), 396 (Mþþ2). Anal. Calcd. for C20H16ClN5O2: C,
60.99; H, 4.09; N, 17.78. Found: C, 60.97; H, 4.10; N, 17.79.
4-(4-Chlorophenyl)-2-(2-(1-(2,4-dimethoxyphenyl)ethylidene)
hydrazinyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (19). mp:
230e234 C; Rf: 0.40; Yield: 71%; IR(cm1): 3310 (CONH),
3283 (NH), 2216 (C^N), 1665 (C]O), 1627 (C]N); 1H
NMR (d, ppm) (400 MHz, DMSO-d6): 2.25 (s, 3H, CH3),
3.77 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 6.51 (d, 1H,
J ¼ 8.4 Hz, H50 Arylidene ring), 6.59 (s, 1H, H30 Arylidene
ring), 7.59 (d, 2H, J ¼ 8.4 Hz, H3,5 Phenyl ring), 7.72 (d, 1H,
J ¼ 8.4 Hz, H60 Arylidene ring), 7.84 (d, 2H, J ¼ 8.0 Hz, H2,6
Phenyl ring), 11.57 (bs, 2H, NH & CONH); MS: m/z 424
(Mþþ1), 426 (Mþþ2). Anal. Calcd. for C21H18ClN5O3: C,
59.51; H, 4.28; N, 16.52. Found: C, 59.53; H, 4.29; N, 16.53.
4-(4-Chlorophenyl)-2-(2-(1-(4-chlorophenyl)ethylidene)hydra-
zinyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (20). mp: 254e
256 C; Rf: 0.64; Yield: 75%; IR(cm1): 3296 (CONH), 3269
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5: X=H, R=H;                    6: X=H, R=4-CH3;            7: X=H, R=4-OH;                   8: X=H, R=4-OCH3; 
9: X=H, R=2,4-diOCH3;   10: X=H, R=4-Cl;             11: X=H, R=4-F;                    12: X=H, R=4-NH2; 
13:X=H, R=4-NO2;           14: X=4-Cl, R=H;             15: X=4-Cl, R=4-CH3;           16: X=4-Cl, R=4-OH; 
17:X=4-Cl, R=4-NO2;       18: X=4-Cl, R=4-OCH3;   19: X=4-Cl, R=2,4-diOCH3;  20: X=4-Cl, R=4-Cl; 
21: X=4-Cl, R=4-F;           22: X=4-Cl, R=4-NH2;     23:X=4-Cl, R=4-Br
Reagents and conditons (i) K2CO3, absolute alcohol, reflux; (ii) NH2NH2.H2O, absolute alcohol, reflux 
                                       (iii) acetic acid and ehanol (2:8), substituted acetophenone, reflux.
Scheme 1:
Synthesis and anticonvulsant activity 441(NH), 2218 (C^N), 1672 (C]O), 1629 (C]N); 1HNMR (d,
ppm) (400 MHz, DMSO-d6): 2.35 (s, 3H, CH3), 7.43 (d, 2H,
J ¼ 8.4 Hz, H30,50 Arylidene ring), 7.59 (d, 2H, J ¼ 8.0 Hz,
H3,5 Phenyl ring), 7.86 (d, 2H, J ¼ 8.4 Hz, H2,6 Phenyl ring),
8.13 (d, 2H, J ¼ 8.4 Hz, H20,60 Arylidene ring), 11.58 (bs, 1H,
NH), 12.18 (bs, 1H, CONH); MS: m/z 399 (Mþþ1), 401
(Mþþ2). Anal. Calcd. for C19H13Cl2N5O: C, 57.30; H, 3.29;
N, 17.59. Found: C, 57.31; H, 3.28; N, 17.60.
4-(4-Chlorophenyl)-2-(2-(1-(4-fluorophenyl)ethylidene)hydra-
zinyl)-6-oxo-1,6 dihydropyrimidine-5-carbonitrile (21). mp: 280e
284 C; Rf: 0.46; Yield: 86%; IR(cm1): 3306 (CONH), 3275
(NH), 2214 (C^N), 1674 (C]O), 1632 (C]N); 1HNMR (d,
ppm) (400 MHz, DMSO-d6): 2.35 (s, 3H, CH3), 7.19 (t, 2H,
J ¼ 8.8 Hz, H30,50 Arylidene ring), 7.59 (d, 2H, J ¼ 8.4 Hz,
H3,5 Phenyl ring), 7.85 (d, 2H, J ¼ 8.8 Hz, H2,6 Phenyl ring),
8.16 (m, 2H, H20,60 Arylidene ring), 11.90 (bs, 2H, NH &
CONH); MS: m/z 382 (Mþþ1), 384 (Mþþ2). Anal. Calcd.
for C19H13ClFN5O: C, 59.77; H, 3.43; N, 18.34. Found: C,
59.76; H, 3.45; N, 18.35.
2-(2-(1 -(4-Aminopheny l)e thy l idene)hydraz iny l) -4-(4 -
chlorophenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (22).
mp: 240e242 C; Rf: 0.43; Yield: 53%; IR(cm1): 3308
(CONH), 3280 (NH), 3274 & 3246 (NH2), 2216 (C^N),
1674 (C]O), 1625 (C]N); 1H NMR (d, ppm) (400 MHz,
DMSO-d6): 2.34 (s, 3H, CH3), 5.50 (s, 2H, NH2), 7.51 (d, 2H,
J ¼ 8.4 Hz, H30,50 Arylidene ring), 7.59 (d, 2H, J ¼ 8.4 Hz,
H3,5 Phenyl ring), 7.84 (d, 2H, J ¼ 8.4 Hz, H2,6 Phenyl ring),
7.96 (d, 2H, J ¼ 8.4 Hz, H20,60 Arylidene ring), 11.43 (bs, 1H,
NH), 11.61 (bs, 1H, CONH); MS: m/z 379 (Mþþ1), 381
(Mþþ2). Anal. Calcd. for C19H15ClN6O: C, 60.24; H, 3.99;
N, 22.19. Found: C, 60.22; H, 3.98; N, 22.17.2-(2-(1-(4-Bromopheny l)e thy l idene)hydraz iny l) -4 -(4-
chlorophenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (23).
mp: 302e306 C; Rf: 0.52; Yield: 56%; IR(cm1): 3318
(CONH), 3280 (NH), 2224 (C^N), 1678 (C]O), 1627 (C]
N); 1H NMR (d, ppm) (400 MHz, DMSO-d6): 2.34 (s, 3H,
CH3), 7.57 (d, 2H, J ¼ 8.4 Hz, H30,50 Arylidene ring), 7.61 (d,
2H, J ¼ 8.0 Hz, H3,5 Phenyl ring), 7.86 (d, 2H, J ¼ 8.4 Hz,
H20,60 Arylidene ring), 8.06 (d, 2H, J ¼ 8.4 Hz, H2,6 Phenyl
ring), 11.59 (bs, 1H, NH), 12.21 (bs, 1H, CONH); MS: m/z
443 (Mþ), 445 (Mþþ2). Anal. Calcd. for:C19H13BrClN5O C,
51.55; H, 2.96; N, 15.82. Found: C, 51.59; H, 2.92; N, 15.84.Pharmacology
The female Swiss albino mice used in this study were
housed and used following a previously described method.8Anticonvulsant activity
The synthesized compounds were evaluated for anticon-
vulsant activity using theMES9,10 and scPTZ11 methods with
phenytoin and carbamazepine as standards. The MES test
was performed using an electro-convulsometer (Ugo Basile
57800, Comerio VA, Italy).Maximal electroshock (MES) test. This test was performed
following a previously reported method.9,10Subcutaneous pentylenetetrazole (scPTZ) seizure threshold test.
scPTZ11 was performed using the reported method by
administering PTZ at a dose11 of 60 mgkg1.
Table 1: Anticonvulsant and neurotoxicity screening study of
compounds 5e23.
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Neurotoxicity was examined12 using a previously
reported method.
Compound Anticonvulsant Activity Neurotoxicity
Screening
MESa scPTZa NTa
After
0.5 h
After
4 h
After
0.5 h
After
4 h
After
0.5 h
After
4 hLog P determination
The values of Log P were calculated using the software
‘ChemDraw Ultra 8.0’.5 e e e e e 300
6 300 300 300 300 X X
7 100 300 100 300 e e
8 300 300 e e X X
9 100 300 100 300 e 300
10 100 300 300 300 100 300
11 300 300 e e e 300
12 300 300 300 300 X X
13 100 300 e e e 300
14 100 300 300 300 100 300
15 300 300 300 300 X X
16 100 300 e e e e
17 30 30 30 100 e e
18 100 300 100 300 100 300
19 100 300 100 300 e 300
20 300 300 300 300 X X
21 300 300 300 300 X X
22 100 300 300 300 100 300
23 30 30 100 100 e e
Phenytoin 30 30 e e e e
Carbamazepineb 30 100 100 100 e e
a Doses of 30, 100, and 300 mg kg1 were administered i.p. Test
compounds were suspended in a 0.5% methylcellulose/water
mixture or in polyethylene glycol (PEG). The values in the table
indicate the minimum dose for which bioactivity was observed in
at least half of the mice. The dash () indicates the absence of
activity at the maximum dose administered (300 mg kg1). X
indicates not tested.
b Data from Ref. 15.
Table 2: Comparison of Log P values.
Series Log Pa Experimental (Calculated)
NO2 Substituted Br Substituted
Previous series 2.73 (2.60) 3.45 (3.56)
Current series 2.97 (3.08) 4.33 (4.24)
a cLog P values were determined using the octanol-phosphate
buffer method; experimental values were calculated using
ChemDraw Ultra 8.0.Results and discussion
The synthesis of 6-oxo-4-phenyl-1,6-dihydropyrimidine-
5-carbonitrile derivatives (5e23) was conducted by refluxing
compound 3 or 4 with different substituted acetophenones
for 2e3 h in a mixture of acetic acid and absolute ethanol
(2:8). The formation of Schiff bases involved the attack of
nitrogen as a nucleophile on the carbonyl group, followed by
deprotonation of nitrogen, and finally displacement of a
water molecule, leaving a C]N bond.
The required intermediate, compound 3 or 4, was ob-
tained upon nucleophilic attack by hydrazine hydrate.
Compound 1 or 2 was synthesized using a modified Biginelli
condensation14 with aromatic aldehyde, ethyl cyanoacetate
and thiourea in the presence of potassium carbonate.
The identities of all compounds were elucidated by IR,
NMR and mass spectrometry. The peak for C]O was
observed in the region of 1655e1703 cm1. The peak for
C^N peak appeared in the region of 2208e2224 cm1. A
sharp peak in the range of 3137e3283 cm1 indicated the
presence of a NH group. The formation of Schiff base was
confirmed by the absence of a NH2 peak and the presence of
a peak for C]N in the range of 1622e1632 cm1.
In the 1H-NMR data, characteristic peaks with appro-
priate multiplicities were observed at different chemical shift
values. In the case of fluoro-substituted compounds (11 &
21), coupling was observed between fluorine and hydrogens
(same spin of 1/2), which resulted in a triplet at d values of 7.02
and 7.19 ppm. In the mass spectra, Mþþ2 peaks were
observed for compounds possessing chlorine and bromine
atoms.
These compounds were assessed for their anticonvulsant
potential using the MES and scPTZ methods. Following
administration of the compounds at doses of 30,100 and
300 mgkg1, anticonvulsant activity was recorded time in-
tervals of 0.5 and 4 h using phenytoin and carbamazepine as
the reference drugs. Neurotoxicity screening of a few selected
compounds was performed using the rotarod test method.
From the anticonvulsant evaluation, compounds 7, 9, 10,
13, 14, 16, 18, 19 and 22 were found to be moderately active.
Nitro (17) and bromo substitution (23) on ring C and chloro
substitution on ring A (Figure 4) were found to be the most
active. Both of these compounds exhibited activity in both
the MES and scPTZ models at the lower dose of 30
mgkg1 at 0.5 and 4 h. The activity of these compounds
was found to be comparable to that of the reference drug
phenytoin and higher than that of carbamazepine.
Compounds 6, 8, 11, 12, 15, 20 and 21 were the least
active, and compound 5 was found to be inactive in both
models (Table 1). During the neurotoxicity screening, it
was observed that compounds 17 and 23 did not present
any signs of motor impairment, even at higher doses.The Log P values for nitro- and bromo-substituted com-
pounds (Figure 3) were found to be higher in the present
series compared to those in the previous one8 (Table 2). In
addition, compounds 17 and 23 of this series exhibited
anticonvulsant activity at a lower dose of 30 mgkg1 after
0.5 and 4 h. From the results, it is evident that increased
values of Log P, i.e., increased lipophilicity, led to
increased anticonvulsant activity. In addition, the most
active compounds of this series did not exhibit any signs of
neurotoxicity even at higher doses, which were observed in
the previous series. Due to this property of increased
Synthesis and anticonvulsant activity 443lipophilicity, these compounds are expected to have a quick
onset of action.
Based on the above results, the following conclusions can
be drawn:
i. Increased lipophilicity in ring A increases anticonvulsant
activity.
ii. In both the previous and current series, the NO2-
substituted compound was found to be the most active.
This result indicates that increased lipophilicity on ring C
does not have a significant effect on anticonvulsant
activity.
iii. The most active compounds of the series did not present
any signs of neurotoxicity.Conclusion
Nineteen new 6-oxo-4-aryl-1,6-dihydropyrimidine-5-
carbonitrile derivatives were synthesized. Among these
newer derivatives, compounds 17 and 23 emerged as the lead
anticonvulsant agents. The anticonvulsant activity of the
compounds in this series was found to be better than that in
the previous series. Compounds 17 and 23 exhibited activity
at a lower dose of 30 mgkg1 at 0.5 and 4 h. In contrast, the
most active compounds of the previous series exhibited ac-
tivity at doses of 30 mgkg1 at 0.5 h and 100 mgkg1 at 4 h.
The anticonvulsant activity of compounds 17 and 23 was
comparable to that of phenytoin and higher than that of
carbamazepine. In addition to better anticonvulsant activity,
compounds 17 and 23 did not show any motor impairment,
which was observed in the previous series. The better results
for this series of compounds in terms of anticonvulsant ac-
tivity and neurotoxicity are a consequence of the increased
lipophilicity.
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